For those who are pregnant or trying to conceive, managing Attention Deficit Hyperactivity Disorder (ADHD) can feel particularly challenging. The prospect of medications that help manage ADHD symptoms can be daunting when considering their potential impact on both the individual and the developing baby. It’s essential to approach this subject with a blend of understanding, evidence-based information, and support.
Understanding ADHD and Its Treatment
ADHD affects many individuals, and symptoms can include inattention, hyperactivity, and impulsiveness. For many, managing these symptoms often provides for the use of medication, particularly stimulants like methylphenidate and amphetamines and/or non-stimulants like atomoxetine or bupropion. However, the safety of these medications during pregnancy and lactation is a common concern and the decision whether to continue on medication or discontinue is complex. A
recent study showed almost 60% of women discontinued their ADHD medication and only 17% re-initiated medication in the postpartum period.
Stimulant Medications
Research indicates that stimulant medications generally pose a low risk of serious complications during pregnancy. A
comprehensive review found no substantial evidence linking the use of these medications with severe birth defects and a
population based study demonstrated no increased risk of any developmental disorders in newborns exposed in utero to ADHD medications compared to those unexposed. However,
some studies suggest a very small increased risk of cardiac malformation in methylphenidate-exposed infants. In women with histories of hypertensive disorders, panic disorder or who are at increased risk of hypertensive disorders in pregnancy,
studies suggest gestational hypertension was significantly associated with stimulant use. For women currently taking stimulants, a carefully monitored continuation of medication may be advisable, especially for those whose ADHD symptoms significantly affect their ability to function optimally.
Non-Stimulant Medications
Non-stimulant options, such as atomoxetine, also present a mixed picture.
Current data suggests that atomoxetine may be safer than its stimulant counterparts, with limited evidence of adverse pregnancy outcomes and
bupropion data is reassuring but demonstrates a very small absolute increased risk of cardiac malformation. However, rigorous studies are still ongoing, and individual responses can vary. Maintaining an open line of communication with your healthcare provider is crucial to tailor a plan that feels right for you.
Lactation Considerations
For new parents choosing to provide breastmilk, continuing ADHD medication is yet another layer to consider.
Studies on the use of stimulants during lactation are limited and therefore the impacts on exposed infants and effects on milk supply are unclear but appear to be reassuring. There are many factors that contribute to the potential effects including the age of the baby, whether or not the baby is exclusively receiving breastmilk, the dose of medication, and the formulation (immediate vs sustained or extended-release). In lactation, using an immediate-release formulation could provide more flexibility and predictability related to peak blood levels. However, it’s essential to proceed with caution and consult your healthcare provider to ensure that you’re making informed decisions that prioritize your health and your baby's.
Making Informed Choices
The decision to use ADHD medication during pregnancy and lactation should be approached thoughtfully. Each individual’s circumstances are unique, and many factors – including the severity of ADHD symptoms, the potential risks of untreated ADHD, and the overall health of both the individual and child – must be considered.
It’s vital to have open dialogues with healthcare professionals who can provide personalized advice and up-to-date information based on the latest research. If you’re considering stopping your medication, discuss alternative strategies for managing symptoms during this crucial time as
studies have shown that discontinuing medication can increase depressive symptoms in pregnancy and postpartum. Behavioral therapies or
support groups can provide significant assistance and can be especially helpful for those who may not feel entirely comfortable with medication use while pregnant.
ADDitude is a trusted online resource sharing the latest evidence and providing guidance and support for living better with ADHD.
Closing Thoughts
If you’re pregnant or trying to conceive and manage ADHD, it is essential to recognize your needs, seek support, and advocate for your health and well-being. Remember, informed choices can empower you to make the best decision, whether that involves medication or alternative approaches. Your mental health is important, we are here to assist you in managing your ADHD with care and understanding as it is a vital part of your journey throughout parenthood.
References
Andersson A, Garcia-Argibay M, Viktorin A, Ghirardi L, Butwicka A, Skoglund C, Madsen KB, D’onofrio BM, Lichtenstein P, Tuvblad C, Larsson H.
Depression and anxiety disorders during the postpartum period in women diagnosed with attention deficit hyperactivity disorder. J Affect Disord. 2023 Jan 18: S0165-0327(23)00085-X.
Baker AS, Wales R, Noe O, Gaccione P, Freeman MP, Cohen LS.
The Course of ADHD during Pregnancy. J Atten Disord. 2022 Jan;26(2):143-148.
Bang Madsen K, Bliddal M, Skoglund CB, Larsson H, Munk-Olsen T, Madsen MG, Hove Thomsen P, Bergink V, Srinivas C, Cohen JM, Brikell I, Liu X.
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period. CNS Drugs. 2024 Apr;38(4):303-314.
Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW, Kildegaard H, Groth JB, Newcorn JH, Hove Thomsen P, Munk-Olsen T, Bergink V.
In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry. 2023 Feb 9.
Newport DJ, Hostetter AL, Juul SH, Porterfield SM, Knight BT, Stowe ZN.
Prenatal Psychostimulant and Antidepressant Exposure and Risk of Hypertensive Disorders of Pregnancy. J Clin Psychiatry. 2016 Nov;77(11):1538-1545.
Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF.
Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children. JAMA Psychiatry. 2024 Jan 24:e235073.